OXYMETAZOLINE
Clinical safety rating: safe
Animal studies have demonstrated safety
Alpha-2 adrenergic receptor agonist, causing vasoconstriction of nasal blood vessels and reducing nasal congestion.
| Metabolism | Unlikely to be significantly metabolized; minimal hepatic metabolism via CYP450 enzymes. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; after intranasal administration, less than 10% of the dose is excreted unchanged in urine. No significant biliary or fecal elimination. |
| Half-life | Terminal elimination half-life is approximately 5–8 hours. However, the clinical duration of action is longer (up to 12 hours) due to sustained receptor binding and local vasoconstriction. |
| Protein binding | Approximately 55% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 0.8–1.2 L/kg; large Vd indicates extensive tissue distribution, especially to nasal mucosa and eyes. |
| Bioavailability | Intranasal: ~50–60% due to mucosal absorption and first-pass metabolism; negligible oral bioavailability due to extensive hepatic metabolism. |
| Onset of Action | Intranasal: 1–2 minutes; Ophthalmic: 2–5 minutes. |
| Duration of Action | Intranasal: up to 12 hours; Ophthalmic: 4–6 hours. Tolerance may develop with prolonged use (rebound congestion). |
Intranasal: 0.05% solution, 2-3 sprays per nostril every 10-12 hours, not to exceed 2 doses in 24 hours. Ophthalmic: 0.025% solution, 1-2 drops in affected eye(s) every 6 hours as needed.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children 2-5 years (intranasal): 0.025% solution, 2-3 sprays per nostril every 10-12 hours, not to exceed 2 doses in 24 hours. Children ≥6 years: Same as adult. Ophthalmic use not recommended in children <2 years. |
| Geriatric use | No specific dose adjustment required; use with caution due to increased risk of rebound congestion and systemic effects (e.g., hypertension, tachycardia) in elderly patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
MAOIs can cause hypertensive crisis Can cause rebound congestion (rhinitis medicamentosa) with prolonged use.
| Breastfeeding | Excreted into breast milk in low amounts; M/P ratio not established. Use with caution, especially with prolonged use or high doses due to potential for infant vasoconstriction and hypertension. Avoid application to nipple area. |
| Teratogenic Risk | Pregnancy Category C. No adequate studies in pregnant women. In animal studies, oxymetazoline was not teratogenic in rats and rabbits at doses up to 500 times the human dose. However, potential for uterine contractions due to systemic vasoconstriction; avoid excessive use especially in first trimester. Risk of fetal bradycardia and hypoxia with maternal hypotension from overdose. |
■ FDA Black Box Warning
None.
| Common Effects | Rebound congestion |
| Serious Effects |
["Hypersensitivity to oxymetazoline","Transsphenoidal hypophysectomy","Narrow-angle glaucoma"]
| Precautions | ["Do not use for more than 3 days to avoid rebound congestion (rhinitis medicamentosa)","Caution in patients with cardiovascular disease, hypertension, hyperthyroidism, diabetes, and prostatic hypertrophy","Avoid in patients with narrow-angle glaucoma"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate during prolonged use. Fetal heart rate monitoring if maternal hypertension or symptoms of systemic toxicity occur. Assess for signs of fetal distress if overdose suspected. |
| Fertility Effects | No known direct effect on fertility. However, potential for reduced ovarian blood flow due to vasoconstriction with systemic absorption, but data are lacking. Use minimal effective dose. |